FIG 6.
Anticancer activities (IC50) of compounds 1 to 3. (A) Bioevaluation of compounds 1 to 3 against the human lung cancer cell line A549. (B) Bioevaluation of compounds 1 to 3 against the human cervical cancer cell line HeLa. (C) Bioevaluation of compounds 1 to 3 against the human colon cancer cell line HCT116.
